Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
There is no experience from controlled clinical trials with concomitant use of Samsca and other
treatments for hyponatremia such as hypertonic sodium chloride solution, oral sodium formulations,
and medicinal products that increase serum sodium concentration. Medicinal products with high
sodium content such as effervescent analgesic preparations and certain sodium containing treatments
for dyspepsia may also increase serum sodium concentration. Concomitant use of Samsca with other
treatments for hyponatremia or other medicinal products that increase serum sodium concentration
may result in a higher risk for developing rapid correction of serum sodium (see section 4.4) and is
therefore not recommended during initial treatment or for other patients with very low baseline serum
sodium concentrations where rapid correction may represent a risk for osmotic demyelination (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
There is no experience from controlled clinical trials with concomitant use of tolvaptan and other
treatments for hyponatremia such as hypertonic sodium chloride solution, oral sodium formulations,
and medicinal products that increase serum sodium concentration. Medicinal products with high
sodium content such as effervescent analgesic preparations and certain sodium containing treatments
for dyspepsia may also increase serum sodium concentration. Concomitant use of tolvaptan with other
treatments for hyponatremia or other medicinal products that increase serum sodium concentration
may result in a higher risk for developing rapid correction of serum sodium (see section 4.4) and is
therefore not recommended during initial treatment or for other patients with very low baseline serum
sodium concentrations where rapid correction may represent a risk for osmotic demyelination (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2026-01-09T14:08:00Z · SHA-256 e5cc431484f1a3971a363d7b3b6f493c7d2e7f54e8577ef36962283646d9be6a · Passage 055fd9fcf5df2527b44f401ee79d259ee47bf199353cab32f9c192ab0692b841 · Zeichen 122–1024 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.